Share >  
Share
Share on Tumblr

Agile Pharma

News »

   latest by relevance
NAVs slips led by weak global and local cues
May 15, 2012 at 09:51 | Source: Moneycontrol.com
Equity funds yet again ended in a red zone for the fifth consecutive session led by weak market condition. The session ended with BSE losing 77.14 points or 0.47% at 16,215.84 while NSE was down by 21.10 points which close at 4,907.80.
NAVs surge led by uptick in the market
Apr 04, 2012 at 10:09 | Source: Moneycontrol.com
Equity funds advanced as markets continued with its positive rally. The BSE benchmark rose 119.27 points or 0.68%, to close at 17,597.42. Meanwhile, the NSE benchmark was up 40.60 points at 5,358.50.
NAVs rise as market cheers on account of low inflation no
Feb 15, 2012 at 09:39 | Source: Moneycontrol.com
The markets cheered on release of inflation data. The 26-month low January inflation data gave a fillip to rate sensitive stocks in anticipation of policy interest rate cuts from RBI. The Sensex closed at 17848.57 up 75.73 points and the Nifty ends at 5427.45 up 37.25 points.
Volatile market cause NAVs to end lower
Feb 11, 2012 at 11:21 | Source: Moneycontrol.com
It was a volatile session in the market! The downtrend in global markets had negatively impacted market sentiments. The Sensex was down by 82.06 point or -0.46 % and closed at 17748.69 while Nifty fell over 90.75 point or 0.57% to end at 5381.60.
NAVs ended mixed amid market volatility
Jan 17, 2012 at 09:56 | Source: Moneycontrol.com
Equity funds managed to register positive returns amid volatile surrounding. The market was seen in pressure due to weak Asian cues and tracking a series of downgrades in Europe by rating agency S&P. The Sensex rose 34.74 points, to close at 16,189.36 and the Nifty went up 7.9 points to 4,873.90.
NAVs end with positive returns
Jul 26, 2011 at 01:01 | Source: Moneycontrol.com
Equity diversified NAVs ended positive with advance:decline ratio of 242:10 as the Indian equity benchmarks continued their uptrend for the second consecutive session - the Sensex added nearly 149 points ahead of RBI policy meet.

Photos »

  /  
Related News »
Veeva Systems Announces Dramatic Growth in Europe
future-proof and agile enough to grow with our organisational needs. Veeva CRM was the only solution to meet all these business requirements," said Wim Kockelkoren, senior vice president EMEA Commercial Effectiveness and CEE Region, Astellas Pharma Europe.
May 15, 2012 at 05:10 | Source: Embedded.com
Agilent Sees Improving Trends - Analyst Blog
However, the pharma/biotech and aerospace/defense markets disappointed, declining 7.3% and 3.6% respectively. Revenue by Segment Agilent reports results in three segments: Chemical Analysis, Life Sciences and Electronic Measurement. Agilent's ...
May 15, 2012 at 19:50 | Source: NASDAQ
Agilent Sees Improving Trends
Chemical/energy and industrial/comps were close on its heels with 14.1% and 11.0% growth from the previous quarter. However, the pharma/biotech and aerospace/defense markets disappointed, declining 7.3% and 3.6% respectively. Revenue by Segment Agilent ...
May 15, 2012 at 19:21 | Source: Zacks.com
Agilent Technologies Reports Second-Quarter 2012 Results
Life Sciences revenues grew 1 percent over last year, while orders declined 1 percent year over year. Solid performance in pharma was offset by weakness in academia and government. Second-quarter ROIC was 26 percent (3). Agilent generated $353 ...
May 14, 2012 at 19:58 | Source: Yahoo Finance
Agilent Acquires Cancer In Vitro Diagnostic Firm Dako for $2.2B in Cash
Tissue-based diagnostics firm Dako provides antibodies, reagents, instruments, and software to the clinical pathology market worldwide, and also collaborates with the pharma industry on the development of companion diagnostics. The firm reported ...
May 17, 2012 at 12:17 | Source: Genetic Engineering News
Oracle envisions an integrated health sciences platform
Oracle envisions a connected ecosystem which enables stakeholders to be agile and cost-effective while providing ... The realization that Big Pharma’s R&D departments are not necessarily the best or most optimal source of novel medications ...
May 16, 2012 at 09:33 | Source: Ovum
Agilent Profit Climbs 28%
Life Sciences revenues for the quarter grew 1% year-over-year to $469 million, driven by pharma. Second quarter revenue from the company's Chemical Analysis segment increased 2% from a year earlier to $388 million, with growth continuing in key end markets ...
May 14, 2012 at 21:03 | Source: RTT News

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window